source
- BioNTech and Genentech halt Phase 2 trial of personalized mRNA cancer vaccineBioNTech and its partner Genentech announced the termination of a Phase 2 study evaluating a personalized mRNA cancer vaccine. The decision was made shortly after the trial had entered its second s…
- CRISPR Therapeutics to test highest dose of lipid‑lowering gene editing therapy after mixed durability dataCRISPR Therapeutics presented early‑stage data at the European Society of Cardiology meeting showing that its lipid‑lowering gene editing candidate produced mixed durability results a year after pa…